EA201070534A1 - Стабилизированная суспензия каризбамата для применения в педиатрии - Google Patents

Стабилизированная суспензия каризбамата для применения в педиатрии

Info

Publication number
EA201070534A1
EA201070534A1 EA201070534A EA201070534A EA201070534A1 EA 201070534 A1 EA201070534 A1 EA 201070534A1 EA 201070534 A EA201070534 A EA 201070534A EA 201070534 A EA201070534 A EA 201070534A EA 201070534 A1 EA201070534 A1 EA 201070534A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pediatrics
carisbamate
application
stabilized suspension
stabilized
Prior art date
Application number
EA201070534A
Other languages
English (en)
Other versions
EA019881B1 (ru
Inventor
Роджер Эмбрехтс
Седрик Ле Лерснейдер
Original Assignee
Янссен Фармацевтика, Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40386492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201070534(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика, Н.В. filed Critical Янссен Фармацевтика, Н.В.
Publication of EA201070534A1 publication Critical patent/EA201070534A1/ru
Publication of EA019881B1 publication Critical patent/EA019881B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение предоставляет стабилизированную суспензию каризбамата для применения в педиатрии и у взрослых. Конкретнее, суспензию стабилизируют гипромеллозой (НРМС) для предупреждения роста кристаллов суспендированных частиц и предупреждения рекристаллизации лекарственного средства в полиморфной форме.
EA201070534A 2007-10-31 2008-10-31 Стабилизированная суспензия каризбамата для применения в педиатрии EA019881B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98414407P 2007-10-31 2007-10-31
PCT/IB2008/003331 WO2009056980A1 (en) 2007-10-31 2008-10-31 Stabilized pediatric suspension of carisbamate

Publications (2)

Publication Number Publication Date
EA201070534A1 true EA201070534A1 (ru) 2010-12-30
EA019881B1 EA019881B1 (ru) 2014-07-30

Family

ID=40386492

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070534A EA019881B1 (ru) 2007-10-31 2008-10-31 Стабилизированная суспензия каризбамата для применения в педиатрии

Country Status (26)

Country Link
US (4) US8263652B2 (ru)
EP (1) EP2214637B1 (ru)
JP (3) JP5841333B2 (ru)
KR (1) KR101568681B1 (ru)
CN (2) CN104840971A (ru)
AR (1) AR069125A1 (ru)
AU (1) AU2008320458B2 (ru)
BR (1) BRPI0818118B8 (ru)
CA (1) CA2703971C (ru)
CL (1) CL2008003261A1 (ru)
CO (1) CO6270300A2 (ru)
CR (1) CR11550A (ru)
EA (1) EA019881B1 (ru)
EC (1) ECSP10010208A (ru)
ES (1) ES2432666T3 (ru)
IL (1) IL205352A (ru)
MX (1) MX2010004889A (ru)
MY (1) MY154063A (ru)
NI (1) NI201000076A (ru)
PA (1) PA8801901A1 (ru)
PE (1) PE20090951A1 (ru)
PL (1) PL2214637T3 (ru)
TW (1) TW200934531A (ru)
UY (1) UY31444A1 (ru)
WO (1) WO2009056980A1 (ru)
ZA (1) ZA201003848B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
WO2011107855A2 (en) 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
EP2563763B1 (en) * 2010-04-30 2014-12-31 Bristol-Myers Squibb Company Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
AR088372A1 (es) * 2011-10-19 2014-05-28 Otsuka Pharma Co Ltd Solucion para administracion oral
TWI660748B (zh) * 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
CN103966680A (zh) * 2014-05-04 2014-08-06 东华大学 一种药物缓释纳米纤维的制备方法
TW201717929A (zh) * 2015-05-22 2017-06-01 愛思開生物製藥股份有限公司 包括卡立胺酯之藥物及其於預防、緩解或治療疼痛或癲癎之用途
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
CN105997866B (zh) * 2016-07-13 2019-08-20 成都明慈医药科技有限公司 一种含地塞米松的混悬剂及其制备方法
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
KR102369827B1 (ko) 2020-09-04 2022-03-04 (주)피알지에스앤텍 프로게리닌을 포함하는 나노현탁액 및 이의 제조방법
US20220213802A1 (en) * 2021-01-06 2022-07-07 General Electric Company System for controlling blade clearances within a gas turbine engine
KR102686558B1 (ko) 2022-01-25 2024-07-22 (주)피알지에스앤텍 프로게리닌을 포함하는 과립제 및 이를 이용한 샤셋제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3265728A (en) 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
RU2141821C1 (ru) * 1994-10-14 1999-11-27 Жансен Фармасетика Н.В. Водная суспензия сабелюзола для орального применения и способ ее изготовления
US5698588A (en) 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
WO2001013904A2 (en) * 1999-08-20 2001-03-01 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
RS50505B (sr) * 2001-02-27 2010-03-02 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju anksioznih poremećaja
AP2005003467A0 (en) * 2003-06-17 2006-12-31 Pfizer N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline reuptake inhibitors.
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
MX2009003929A (es) * 2006-10-13 2009-06-26 Janssen Pharmaceutica Nv Composiciones de fenilalquil carbamato.
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate

Also Published As

Publication number Publication date
MX2010004889A (es) 2010-05-19
US8263652B2 (en) 2012-09-11
CA2703971A1 (en) 2009-05-07
UY31444A1 (es) 2009-04-30
US10201519B2 (en) 2019-02-12
BRPI0818118A2 (pt) 2015-08-04
IL205352A0 (en) 2010-12-30
CN104840971A (zh) 2015-08-19
EP2214637A1 (en) 2010-08-11
IL205352A (en) 2014-09-30
PA8801901A1 (es) 2009-06-23
JP6273589B2 (ja) 2018-02-07
US20090111872A1 (en) 2009-04-30
AU2008320458B2 (en) 2014-01-23
CO6270300A2 (es) 2011-04-20
PL2214637T3 (pl) 2013-10-31
CL2008003261A1 (es) 2009-10-16
EA019881B1 (ru) 2014-07-30
NI201000076A (es) 2010-11-10
US20160008476A1 (en) 2016-01-14
AU2008320458A1 (en) 2009-05-07
US20170112798A1 (en) 2017-04-27
ZA201003848B (en) 2011-08-31
JP2011500870A (ja) 2011-01-06
BRPI0818118B8 (pt) 2021-05-25
WO2009056980A1 (en) 2009-05-07
CR11550A (es) 2011-01-14
US9161913B2 (en) 2015-10-20
KR20100092944A (ko) 2010-08-23
BRPI0818118B1 (pt) 2020-05-12
ES2432666T3 (es) 2013-12-04
CA2703971C (en) 2017-10-10
TW200934531A (en) 2009-08-16
US20120309826A1 (en) 2012-12-06
AR069125A1 (es) 2009-12-30
JP2014193913A (ja) 2014-10-09
MY154063A (en) 2015-04-30
KR101568681B1 (ko) 2015-11-12
PE20090951A1 (es) 2009-07-13
EP2214637B1 (en) 2013-05-08
ECSP10010208A (es) 2010-06-29
JP5841333B2 (ja) 2016-01-13
JP2016216486A (ja) 2016-12-22
CN101848699A (zh) 2010-09-29

Similar Documents

Publication Publication Date Title
EA201070534A1 (ru) Стабилизированная суспензия каризбамата для применения в педиатрии
CL2012002771A1 (es) Compuestos derivados de ariletinilo sustituidos, moduladores de los receptores mglur5; proceso de obtencion; composicion farmaceutica; y su uso en el tratamiento o prevencion de la esquizofrenia, enfermedades cognitivas, sindrome de x fragil o el autismo.
EA201291220A1 (ru) Производные аминопиримидина в качестве модуляторов lrrk2
EA201200174A1 (ru) Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
MX2013007295A (es) Quinoxalinas y aza-quinoxalinas como moduladores del receptor de crth2.
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
MX349556B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
EA201490569A1 (ru) Полиморфная форма гидрохлорида придопидина
MX2011013016A (es) Derivados de aminopirrolidinona y usos de los mismos.
EA201001243A1 (ru) Кристаллические формы n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамида и способы их получения
PE20090876A1 (es) Nuevos derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de cmet
EA201270808A1 (ru) Новые формы рифаксимина и их применение
CY1120435T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
CY1118036T1 (el) Βελτιστοποιημενη συνθεση καθαρων μη-πολυμορφικων, κρυσταλλικων χολικων οξεων με καθορισμενο μεγεθος σωματιδιων
MX2010001851A (es) Derivados de indol-2-ona disustituidos en 3, su preparacion y uso terapeutico.
EA201001870A1 (ru) Новые кристаллические формы рабепразола натрия
EA201290229A1 (ru) Производные спиролактама и их применение
MY157425A (en) Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
EA201270377A1 (ru) Стабильные композиции sns-595 и способы их получения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment